Your browser doesn't support javascript.
loading
Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer.
Shoemaker, Robert H; Panettieri, Reynold A; Libutti, Steven K; Hochster, Howard S; Watts, Norman R; Wingfield, Paul T; Starkl, Philipp; Pimenov, Lisabeth; Gawish, Riem; Hladik, Anastasiya; Knapp, Sylvia; Boring, Daniel; White, Jonathan M; Lawrence, Quentin; Boone, Jeremy; Marshall, Jason D; Matthews, Rebecca L; Cholewa, Brian D; Richig, Jeffrey W; Chen, Ben T; McCormick, David L; Gugensberger, Romana; Höller, Sonja; Penninger, Josef M; Wirnsberger, Gerald.
Afiliação
  • Shoemaker RH; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Panettieri RA; Rutgers Institute for Translational Medicine and Science, New Brunswick, New Jersey, United States of America.
  • Libutti SK; Rutgers Cancer Institute, New Brunswick, New Jersey, United States of America.
  • Hochster HS; Rutgers Cancer Institute, New Brunswick, New Jersey, United States of America.
  • Watts NR; Protein Expression Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Wingfield PT; Protein Expression Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Starkl P; Department of Medicine I, Laboratory of Infection Biology, Medical University of Vienna, Vienna, Austria.
  • Pimenov L; Department of Medicine I, Laboratory of Infection Biology, Medical University of Vienna, Vienna, Austria.
  • Gawish R; Department of Medicine I, Laboratory of Infection Biology, Medical University of Vienna, Vienna, Austria.
  • Hladik A; Department of Medicine I, Laboratory of Infection Biology, Medical University of Vienna, Vienna, Austria.
  • Knapp S; Department of Medicine I, Laboratory of Infection Biology, Medical University of Vienna, Vienna, Austria.
  • Boring D; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • White JM; MRIGlobal, Kansas City, Missouri, United States of America.
  • Lawrence Q; MRIGlobal, Kansas City, Missouri, United States of America.
  • Boone J; MRIGlobal, Kansas City, Missouri, United States of America.
  • Marshall JD; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
  • Matthews RL; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
  • Cholewa BD; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Richig JW; IIT Research Institute, Chicago, Illinois, United States of America.
  • Chen BT; IIT Research Institute, Chicago, Illinois, United States of America.
  • McCormick DL; IIT Research Institute, Chicago, Illinois, United States of America.
  • Gugensberger R; Apeiron Biologics AG, Campus-Vienna-Biocenter 5, Vienna, Austria.
  • Höller S; Apeiron Biologics AG, Campus-Vienna-Biocenter 5, Vienna, Austria.
  • Penninger JM; Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.
  • Wirnsberger G; Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada.
PLoS One ; 17(7): e0271066, 2022.
Article em En | MEDLINE | ID: mdl-35816490
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article